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Background: Dillenia suffruticosa root dichloromethane extract (DCM-DS) has been reported to exhibit strong
cytotoxicity towards breast cancer cells. The present study was designed to investigate the cell cycle profile, mode
of cell death and signalling pathways of DCM-DS-treated human caspase-3 deficient MCF-7 breast cancer cells.
Methods: Dillenia suffruticosa root was extracted by sequential solvent extraction. The anti-proliferative activity of
DCM-DS was determined by using MTT assay. The mode of cell death was evaluated by using inverted light microscope
and Annexin-V/PI-flow cytometry analysis. Cell cycle analysis and measurement of intracellular reactive oxygen species
(ROS) were performed by using flow cytometry. MCF-7 cells were co-treated with antioxidants α-tocopherol and ascorbic
acid to evaluate whether the cell death was mainly due to oxidative stress. GeXP-based multiplex system was employed
to investigate the expression of apoptotic, growth and survival genes in MCF-7 cells. Western blot analysis was
performed to confirm the expression of the genes.
Results: DCM-DS was cytotoxic to the MCF-7 cells in a time-and dose-dependent manner. The IC50 values of
DCM-DS at 24, 48 and 72 hours were 20.3 ± 2.8, 17.8 ± 1.5 and 15.5 ± 0.5 μg/mL, respectively. Cell cycle analysis revealed
that DCM-DS induced G0/G1 and G2/M phase cell cycle arrest in MCF-7 cells at low concentration (12.5 and 25 μg/mL)
and high concentration (50 μg/mL), respectively. Although Annexin-V/PI-flow cytometry analysis has confirmed that
DCM-DS induced apoptosis in MCF-7 cells, the distinct characteristics of apoptosis such as membrane blebbing,
chromatin condensation, nuclear fragmentation and formation of apoptotic bodies were not observed under
microscope. DCM-DS induced formation of ROS in MCF-7 cells. Nevertheless, co-treatment with antioxidants did
not attenuate the cell death at low concentration of DCM-DS. The pro-apoptotic gene JNK was up-regulated
whereby anti-apoptotic genes AKT1 and ERK1/2 were down-regulated in a dose-dependent manner. Western
blot analysis has confirmed that DCM-DS significantly up-regulated the expression of pro-apoptotic JNK1, pJNK
and down-regulated anti-apoptotic AKT1, ERK1 in MCF-7 cells.
Conclusion: DCM-DS induced cell cycle arrest and apoptosis in MCF-7 cells via multiple signalling pathways. It
shows the potential of DCM-DS to be developed to target the cancer cells with mutant caspase-3.
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Cancer is a polygenic and multifactorial disease. Cancer
cells often acquire multiple gene mutations that allow the
cells to escape the cell cycle regulation and programmed
cell death [1]. The current understanding of the molecular
cancer biology has revealed that cancers are subdivided
into different pathways. In contrast to the traditional sin-
gle molecule-single target approach, being able to target
two or more pathways at once or a few players in the
same pathway would be a more effective therapy for the
treatment of cancer. This strategy is in parallel to the new
guideline approved by US Food and Drug Administration
(FDA) in 2011 which outlines a path towards developing
combination therapy [1,2]. Thus, evidence-based herbal
medicines might be one of the starts for these approaches.
The mixture of active compounds in the herbal medicines
may have synergistic effect on cancer such as targeting on
several pathways, reducing adverse side effects, and altering
drug metabolism and excretion [3,4]. The formulations of
herbal medicine can be further explored which may lead to
novel insights in pharmacological management of cancer
and other diseases.
Mitogen-activated protein kinases (MAPKs) are a fam-
ily of serine/threonine protein kinases involved in the
early apoptosis that regulate important cellular processes
such as cell survival and adaptation by phosphorylating
numerous cytoplasmic and nuclear targets [5-8]. There
are at least four distinct subgroups of MAPKs, of which
the P38 mitogen-activated protein kinases (p38 MAPKs),
c-Jun N-terminal kinases (JNKs), extracellular signal-
regulated kinases (ERKs) and protein kinase B (PKB or
AKTs) have been extensively described. Generally, p38
MAPKs and JNKs are involved in the induction of apop-
tosis, whereas ERKs and AKTs have been implicated as a
factor involved in cell survival [9-13].
The transcription factor nuclear factor-kappa B (NF-κB)
has been correlated to oncogenesis by upregulating the
expression of survival factors of cancer cells, thereby
inhibiting apoptosis. NF-κB is composed of hetero- or
homodimers of the NF-κB/Rel family of proteins. NF-κB
complexes are sequestered in the cytoplasm in an
inactive form by their interaction with inhibitor of kB
(IkB) proteins [14]. NF-κB activity is induced in response
to a variety of stimuli including inflammatory cytokines,
cellular stress, reactive oxygen species (ROS) or anti-
cancer agents. The activation of IkB kinase (IKK) com-
plexes phosphorylates IkB proteins, triggering their
degradation via the proteasome. NF-κB complexes are
then translocated into the nucleus, bind to specific
DNA-binding sites and regulate the transcription of
target genes [15] including various anti-apoptotic proteins,
but also several pro-apoptotic molecules, consistent with
reports that NF-κB can promote apoptosis under certain
circumstances [16,17].The search for signature genes of different cancers has
shown that most cancers are due to dysregulation of
multiple genes and multiple cell signalling pathways;
thus, drugs that are multi-targeted (once called “dirty
drugs”) are needed. Compounds from natural sources have
an advantage in that they are usually multi-targeted [12].
Dillenia suffruticosa (Griffith ex Hook. F. and Thomson)
Martelli (Family: Dilleniaceae), commonly known as “Sim-
poh air”, is found abundantly in the secondary forest and
swampy ground of Malaysia. This plant is traditionally
used as alternative herbal medicine for the treatment of
cancerous growth including breast cancer [18]. Neverthe-
less, there is no pharmacological study on the anti-breast
cancer properties of the root extract in the literature. In
addition, the plant has also been reported to exhibit anti-
microbial [19] and antiviral properties [20]. Previous stud-
ies conducted in our lab revealed that the root hot water
extract of D. suffruticosa exhibited anti-cervical and colon
cancer properties in rodents (Patent ID: 20120003490)
[21]. In addition, root dichloromethane total extract of D.
suffruticosa (DCM-DS) from sequential solvent extraction
exhibited strong cytotoxicity towards human MCF-7 breast
cancer cells [22]. Therefore, DCM-DS has a great potential
to be developed as evidence-based complementary and
alternative medicine for the treatment of breast cancer.
Nevertheless, the underlying mechanisms of DCM-DS-
induced cytotoxicity in caspase-3 deficient MCF-7 breast
cancer cells remain to be elucidated. This study investi-
gated the cell cycle profile, mode of cell death and signal-
ling pathways of DCM-DS-treated human caspase-3
deficient MCF-7 breast cancer cells.
Methods
Plant material
Fine powder of Dillenia suffruticosa was supplied by Primer
Herber Sdn. Bhd., Malaysia. The plant’s authentication was
performed with the parts of the plants (flower, leaves, stems
and roots) at the Biodiversity Unit, Institute of Bioscience,
Universiti Putra Malaysia, Malaysia (voucher specimen
number SK1937/11).
Preparation of plant extract
DCM-DS from sequential solvent extraction exhibited
strong cytotoxicity towards human MCF-7 breast cancer
cells [22]. Therefore, DCM-DS was employed for the
current study with modification on the extraction method
(Patent ID: 20120003490). Briefly, 100 g of the powdered
root was macerated with 500 μL of hexane (1:5, w/v)
(Friedemann Schmidt, Francfort, Germany) for 2 days at
room temperature with occasional shaking at 200 rpm
(IKA KS 260 basic, IKA, Staufen, Germany). The mixture
was then centrifuged at 2000 × g for 5 min. The super-
natant was filtered through Whatman filter paper No. 1.
The residue was re-extracted until the colour disappeared,
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ated with dichloromethane (DCM) (Friedemann Schmidt,
Francfort, Germany). The combined DCM total extracts
were pooled and DCM was removed under reduced
pressure (Rotavapor R210, Buchi, Flawil, Switzerland). The
percentage of yield for DCM-DS was calculated as: (weight
of extract/weight of powdered root) × 100%.
Cell culture
The human MCF-7 breast cancer and non-tumourigenic
MCF10A cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
MCF-7 cells were grown in phenol-red-free RPMI
1640 with L-glutamine (Nacalai Tesque, Kyoto, Japan),
supplemented with 10% foetal bovine serum (FBS) (PAA,
Pasching, Austria) and 1% penicillin–streptomycin (PAA,
Pasching, Austria). MCF-10A cells were cultured in
DMEM/F12 (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% FBS (PAA, Pasching, Austria),
20 ng/mL epidermal growth factor (Sigma-Aldrich, St.
Louis, MO, USA), 0.5 mg/mL hydrocortisone (Sigma-
Aldrich, St. Louis, MO, USA), 100 ng/mL cholera toxin
(Sigma-Aldrich, St. Louis, MO, USA), and 10 μg/mL insu-
lin (Sigma-Aldrich, St. Louis, MO, USA). The cells used
for each experiment were of less than 20 passage number.
Determination of cell viability
The stock concentration (30 mg/mL) of DCM-DS total
extract was prepared in dimethyl sulfoxide (DMSO)
(Friedemann Schmidt, Francfort, Germany). MCF-7 and
MCF-10A cells were trypsinized (trypsin-EDTA (1×), PAA,
Pasching, Austria) and seeded in 96-well flat-bottomed
plates with 5000 cells per well in 100 μL of complete
growth culture media, followed by incubation at 37°C (5%
CO2 and 95% air) for 24 hours to allow cell attachment.
The cells were then treated with either Tamoxifen (Sigma-
Aldrich, St. Louis, MO, USA) or DCM-DS for 24, 48 and
72 hours. Control cells treated with 0.3% DMSO alone were
also included. DMSO at 0.3% was not toxic to the MCF-7
cells in the present study (unpublished data). Following
incubation, 20 μL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, PhytoTechnology Laborator-
ies, Kansas, USA) (5 mg/mL in PBS) was added into each
well and the plate was incubated for 3 hours. The excess
MTT was then aspirated and the formazan crystals formed
were dissolved by 150 μL of DMSO. The absorbance, which
was proportional to cell viability, was measured at 570 nm
and a reference wavelength of 630 nm by using EL×800™
Absorbance Microplate Reader (BioTek Instruments Inc.,
Vermont, USA). Cell viability was calculated based on the
following equation [23]:
Cell viability %ð Þ ¼ OD570−630 Treatment
OD570−630 Control
 100A graph of percentage of cell viability versus concentra-
tion of DCM-DS was plotted, and the concentration of
DCM-DS which inhibited 50% of cellular growth as com-
pared to the control (IC50 value) was determined [24].
Morphological study
MCF-7 cells were seeded in 6-well plates at 1.3 × 105 cells
per well in 3 mL of complete growth medium, incubated
for 24 hours and treated with DCM-DS (12.5-50 μg/mL).
Control cells treated with 0.3% DMSO alone were also
included. The morphological changes, characteristic of
apoptosis or necrosis, were observed and the images were
captured under an inverted light microscope (Olympus,
PA, USA) at 0, 24, 48 and 72 hours. The same spot of cells
was marked and captured.
Cell cycle analysis
Cells were seeded in 6-well plates at 1.3 × 105 cells in
3 mL of complete growth culture media, incubated for
24 hours and treated with DCM-DS (12.5-50 μg/mL).
Following incubation, the floating cells were collected
and adherent cells were harvested by trypsinisation to
detach the cells and pelleted at 100 × g for 5 min. Cells
were washed twice with PBS and resuspended in 70%
ethanol at −20°C overnight. Prior to analysis, the cells
were washed once with PBS, suspended in 425 μL of PBS,
25 μL of propidium iodide (1 mg/mL, Sigma-Aldrich, St.
Louis, MO, USA) and 50 μL of RNaseA (1 mg/mL,
Sigma-Aldrich, St. Louis, MO, USA), and incubated on ice
for 20 min. The DNA content of 10000 cells was analysed
by FACSCalibur flow cytometer (Becton Dickinson, CA,
USA) and the population of cells in each cell-cycle phase
was determined by using the ModFit LT software.
Determination of apoptosis by Annexin V/PI staining
Experiment was carried out according to the manufac-
turer’s instructions (Annexin V-FITC kit, eBioscience,
Vienna, Austria) with slight modification. Cells were
seeded in 6-well plates at 1.3 × 105 cells per well in 3 mL
of complete growth culture media, incubated for 24 hours
and treated with DCM-DS (12.5-50 μg/mL). Following
incubation, the floating cells were collected and the adher-
ent cells were trypsinized to detach the cells. Cells were
counted and a volume of media containing 1 × 105 cells
(both viable and death cells) was centrifuged at 100 × g to
obtain a pellet. Next, 195 μL of 1× assay buffer and 5 μL
of Annexin V-fluorescein isothiocyanate (FITC) were added
to the pellet. The samples were mixed by gentle tapping.
Following 10 min incubation at room temperature in the
dark, 300 μL of 1× assay buffer and 10 μL of PI (20 μg/mL)
were added, and the samples were analysed immediately
by FACSCalibur flow cytometer (Becton Dickinson, CA,
USA). For each sample, 10000 events were collected. The
results were analysed by using FlowJo software.
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DCM-DS-treated cells
Dichlorodihydrofluorescein diacetate (DCFH-DA, Sigma-
Aldrich, St. Louis, MO, USA) was used to measure intracel-
lular reactive oxygen species (ROS) in DCM-DS-treated
cells. MCF-7 cells were seeded in 6-well plates at 1.3 × 105
cells per well in 3 mL of complete growth culture media,
incubated for 24 hours and pretreated with 10 μM DCFH-
DA in FBS-free culture media for 1 hour. Next, the excess
DCFH-DA was removed. The cells were then washed twice
with PBS and further treated with DCM-DS in FBS-free
culture media for 3 hours. Following incubation, the
floating cells were collected and the adherent cells were
trypsinized to detach the cells. The samples were then
analysed immediately by FACSCalibur flow cytometer
(Becton Dickinson, CA, USA). For each sample, 10000
events were collected. The results were analysed by using
FlowJo software.
Evaluation of antioxidants on DCM-DS-induced cell death
in MCF-7 cells
MCF-7 cells were seeded in 96-well plates (5000
cells/well) and incubated at 37°C (5% CO2 and 95% air)
for 24 hours. The cells were then treated with DCM-DS
or co-treated with 50 μM α-tocopherol or vitamin C
(Sigma-Aldrich, St. Louis, MO, USA) for 24 and 48 hours.
At the end of the experiment, 20 μL MTT (5 mg/mL in
PBS) was added into each well and the plate was incu-
bated for 3 hours. The excess MTT was then aspirated
and the purple formazan crystals were dissolved by 150 μL
of DMSO. The absorbance was measured at 570 nm and a
reference wavelength of 630 nm by using EL×800™ Ab-
sorbance Microplate Reader (BioTek Instruments Inc.,
Vermont, USA). Cell viability was calculated based on the
following equation [23]:
Percentage of cell viability %ð Þ ¼ OD570−630 Treatment
OD570−630 Control
A graph of percentage of cell viability versus concentra-
tion of DCM-DS was plotted, and the concentration of
DCM-DS which inhibited 50% of cellular growth as com-
pared to the control (IC50 value) was determined [24].
RNA extraction
Cells were seeded in 6-well plates at 1.3 × 105 cells per
well in 3 mL of complete growth culture media. After
treatment with DCM-DSE for 24 hours, the floating cells
were collected and the adherent cells were trypsinised to
detach the cells. The cells were centrifuged at 100 × g to
obtain a pellet and washed twice with PBS. RNA was
then isolated from the cells using the Real Genomics Total
RNA Extraction Kit (RBCBioscience, Taipei, Taiwan).
Briefly, the cells were mixed with 100 μL of lysis buffer,
400 μL of RB buffer and 4 μL of β-mercaptoethanol, andincubated for 5 min on ice. After incubation, 400 μL of
70% ethanol was added. Vigorous pipetting was performed
to break any precipitate. The mixture was then transferred
to RT column and centrifuged at 1000 × g for 2 min to
bind RNA to the column. The RT column was transferred
to a new collection tube, washed once with W1 Buffer and
2 times with Wash Buffer. Finally, the RT column was
transferred to another new collection tube. RNAse-free
water (50 μL) was added into the column matrix to
dissolve the RNA. The RT column was centrifuged at
1000 × g for 1 min to elute purified RNA. The RNA
concentration and quality were checked by a nano-
photometer (Implen, Baxter Avenue, Britain).
cDNA synthesis
RNA was reverse transcribed with multiplex universal
reverse primers (Table 1) according to the GenomeLab™
GeXP Start Kit (Beckman Coulter Inc, CA, USA) from
Beckman Coulter protocol with slight modification. Briefly,
50 ng of RNA (1 μL) from each sample was mixed with
1 μL of KANr RNA, 1 μL of reverse transcriptase, 2 μL of
multiplex universal reverse primers, 4 μL of 5× reverse
transcription buffer and 11 μL of RNAse-free water. The
total volume for each sample was 20 μL. The reverse tran-
scription was performed in a XP Thermal Cycler (Bioer
Technology, Hangzhou, China) with the following mode:
48°C for 1 min; 42°C for 60 min; 95°C for 5 min and hold
at 4°C.
Polymerase chain reaction
Following reverse transcription, polymerase chain reaction
(PCR) was performed to amplify the amount of cDNA
according to the GenomeLab™ GeXP Start Kit (Beckman
Coulter Inc, CA, USA) from Beckman Coulter protocol.
cDNA from each sample (9.3 μL) was mixed with 2 μL of
200 nM forward universal primer mixture, 4 μL of 25 mM
MgCl2, 4 μL of 5× PCR Master Mix buffer and 0.7 μL of
Taq polymerase. The total volume for each sample was
20 μL. Amplification conditions consisted of 95°C for
10 min, followed by 35 cycles of 94°C for 30 sec, 55°C for
30 sec and 70°C for 1 min. The reactions were performed
in a XP Thermal Cycler (Bioer Technology, Hangzhou,
China).
Gene multiplex data analysis
PCR product (l μL) was mixed with 38.5 μL of sample
loading solution along with 0.5 μL of DNA Size Standard
400 (GenomeLab GeXP Start Kit, Beckman Coulter, Inc)
and analysed on a GeXP genetic analysis system (S.Kraemer
Boulevard, USA). The GeXPS system was used to separate
PCR products based on size by capillary gel electrophoresis
and to measure their dye signal strength in arbitrary units
(A.U.) of optical fluorescence, defined as the fluorescent
signal minus background.
Table 1 Genes used in GeXP multiplex analysis
Name Accession number Left sequence w/Universals Right sequence w/Universals
JNK NM_139046 AGGTGACACTATAGAATACAGAAGCTCCACCACCAAAGAT GTACGACTCACTATAGGGAGCCATTGATCACTGCTGCAC
18SRNAa M10098 AGGTGACACTATAGAATAGGAGTGGAGCCTGCGGCTTAA GTACGACTCACTATAGGGATAGCATGCCAGAGTCTCGTT
ERK1/2 NM_002745 AGGTGACACTATAGAATAGGAGCAGTATTACGACCCGA GTACGACTCACTATAGGGAGATGTCTGAGCACGTCCAGT
AKT1 NM_001014431 AGGTGACACTATAGAATAGAGGAGATGGACTTCCGGTC GTACGACTCACTATAGGGAAGGATCTTCATGGCGTAGTAGC
NF-κB NM_001077493 AGGTGACACTATAGAATAGCGGGCGTCTAAAATTCTG GTACGACTCACTATAGGGATTCCACGATCACCAGGTAGG
ACTBa NM_001101 AGGTGACACTATAGAATAGATCATTGCTCCTCCTGAGC GTACGACTCACTATAGGGAAAAGCCATGCCAATCTCATC
GAPDHa NM_002046 AGGTGACACTATAGAATAAAGGTGAAGGTCGGAGTCAA GTACGACTCACTATAGGGAGATCTCGCTCCTGGAAGATG
p38MAPK NM_001315 AGGTGACACTATAGAATATTCAGTCTTTGACTCAGATGCC GTACGACTCACTATAGGGAGTCAGGCTTTTCCACTCATCT
Kan(r)b AGGTGACACTATAGAATAATCATCAGCATTGCATTCGATTCCTGTTTG GTACGACTCACTATAGGGAATTCCGACTCGTCCAACATC
SOD1 NM_000454 AGGTGACACTATAGAATATCATCAATTTCGAGCAGAAGG GTACGACTCACTATAGGGATGCTTTTTCATGGACCACC
SOD2 NM_000636 AGGTGACACTATAGAATACATCAAACGTGACTTTGGTTC GTACGACTCACTATAGGGACTCAGCATAACGATCGTGGTT
CAT NM_001752 AGGTGACACTATAGAATAGAAGTGCGGAGATTCAACACT GTACGACTCACTATAGGGAACACGGATGAACGCTAAGCT
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The data were analysed using the Fragment Analysis
module of the GeXP system software and imported into
the analysis module of eXpress Profiler software. Fold
change was normalised against beta actin.
Western blot analysis
Bovine serum albumen (BSA), phosphatase inhibitor
cocktails and Chemi-Lumi One L were purchased from
Nacalai Tesque (Kyoto, Japan). Phenylmethanesulfonyl
fluoride (PMSF) and protease inhibitor cocktails were
purchased from Calbiochem (San Diego, CA, USA). So-
dium dodecyl sulphate (SDS), Triton-X 100, Tris-base,
glycine, acrylamide, bisacrylamide, ammonium persul-
fate (APS), tetramethylethylenediamine (TEMED), 10%
Tween-20, Bradford Reagent, 2-mercaptoethanol, extra
thick blotting paper and pre-stained protein marker were
purchased from Bio-Rad (California, USA). Immobilon-FL
polyvinylidene fluoride (PVDF) membrane with 0.45 μm
pore size was purchased from Millipore (Bedford, MA,
USA). Rabbit anti-AKT1 (ab32505), rabbit anti-ERK1
(ab32537), rabbit anti-JNK1 (ab10664), rabbit anti-p-JNK1
(ab47337), rabbit anti-NF-ҡB p65 (ab7970) and mouse
anti-beta-actin (ab8226) primary antibodies were pur-
chased from ABCAM (Cambridge, MA, USA). Horse-
radish peroxidase-conjugated goat anti-rabbit (ab6721)
and goat anti-mouse (ab97240) secondary antibodies
were purchased from ABCAM (Cambridge, MA, USA).
MCF-7 cells were seeded into 75 cm2 tissue culture
flasks at 800,000 cells per flask with 15 mL of complete
growth culture media and incubated for 24 hours. After
treatment with DCM-DS for 24 and 48 hours, the float-
ing cells were collected in a 50 mL centrifuge tube and
washed twice with cold PBS. The adherent cells were
also washed twice with cold PBS, lysed with 200 μL of
cold lysis buffer (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 0.1% SDS (w/v), 1% Triton-X 100 (v/v), 0.5% so-
dium deoxycolate (w/v)). PMSF (1 mM), protease inhibi-
tor cocktails (10 μL/mL of lysis buffer) and phosphatase
inhibitor cocktails (10 μL/mL of lysis buffer) were added
to the cold lysis buffer prior to lysis of the cells. The
flasks were then kept on ice for 5 min with occasionally
swirling the flasks for uniform spreading of the lysis
buffer. The lysate was gathered at one side using a cell
scraper, collected with 1 mL pipette, pooled with the
floating cells, transferred to a microcentrifuge tube and
centrifuged at 14,000 × g for 10 min to pellet the cell
debris. The clarified supernatant was then collected and
stored at −80°C. The protein concentration quantification
was performed by using Bradford Protein Assay. An equal
amount of 10–20 μg of proteins was separated by 12%
SDS-PAGE. After electrophoresis, the proteins were
transferred to PVDF membrane by semi-dry transfer
method, blocked with 3% BSA in 0.1% Tween-20containing Tris-Buffer Saline (TBS-T) at room temperature
(20–25°C) for 1 hour, reacted with anti-AKT1 (1:10,000),
anti-ERK1 (1:5000), anti-JNK1 (1:10,000), anti-p-JNK1
(1:5000), anti-NF-ҡB p65 (1:5000) and anti-beta-actin
(1:10,000) primary antibodies in TBS-T overnight at 4°C.
After washing 3 times with TBS-T at room temperature,
the primary antibodies were either reacted with horserad-
ish peroxidase-conjugated goat anti-rabbit (1:40,000) or
goat anti-mouse (1:40,000) secondary antibodies in TBS-T
for 1 hour at room temperature. The protein visualisation
was then performed by using Chemi-Lumi One L and
ChemiDoc™ MP System (Bio-Rad, Hercules, CA, US) in a
dark room.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Science (SPSS) version 21.0. Data
were expressed as mean ± standard deviation (mean ± SD).
Results were analysed by one-way analysis of variance
(ANOVA), followed by Post Hoc Multiple Comparisons.
A difference was considered to be significant at p < 0.05.
Results
DCM-DS was cytotoxic and inhibited growth of MCF-7 cells
DCM-DS was cytotoxic towards MCF-7 cells in a dose-
and time-dependent manner (Figure 1A). Treatment with
DCM-DS at higher concentrations (12.5-100 μg/mL)
resulted in significant reduction (p < 0.05) in the cell
viability. The IC50 values of DCM-DS towards MCF-7
cells at 24, 48 and 72 hours were 20.3 ± 2.8, 17.8 ± 1.5
and 15.5 ± 0.5 μg/mL, respectively. The IC50 value of
Tamoxifen towards MCF-7 cells at 72 hours was 7.0 ±
1.0 μg/mL. In addition, DCM-DS was also cytotoxic to-
wards MCF-10A cells in a dose- and time-dependent
manner (Figure 1B). The IC50 values of DCM-DS towards
MCF-10A cells at 24, 48 and 72 hours were 37.6 ± 4.3,
24.0 ± 2.2 and 10.3 ± 2.1 μg/mL, respectively.
Morphological study revealed that DCM-DS induced
growth inhibition and apoptosis in MCF-7 cells. As
shown in Figure 2A and 2C, the number of cells in the
control and the one treated with 12.5 μg/mL of DCM-
DS increased from 0 to 72 hours. Nevertheless, the cells
in the latter demonstrated cellular shrinkage at 48 hours
(Figure 2B) and this phenomenon became more obvious
at 72 hours. For the cells treated with DCM-DS at
25 μg/mL, increase in the cell population was noted
until 24 hours. In the following hour, the growth was
inhibited and the cells detached from the substratum
(Figure 2A and 2B). Majority of the cells treated with
DCM-DS at 50 μg/mL detached from the substratum at
48 and 72 hours (Figure 2A). Other characteristics of
apoptosis such as membrane blebbing, chromatin conden-
sation, nuclear fragmentation and formation of apoptotic
bodies or necrosis were not observed (Figure 2B).
BA
C
Figure 1 Effect of DCM-DS on the viability of MCF-7 breast cancer and non-tumorigenic MCF10A cells as determined by MTT assay.
Cytotoxic effect of DCM-DS was evaluated on (A) MCF-7 and (B) MCF-10A cells. The extract was cytotoxic to the cells in a dose- and time-dependent
manner. (C) Antiproliferative effect of Tamoxifen on MCF-7 cells . Each data point represents the mean of three independent experiments ± SD.
*significantly different from the control (p < 0.05).
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MCF-7 cells
Treatment with DCM-DS at 12.5 and 25 μg/mL signifi-
cantly increased (p < 0.05) the population of cells at G0/G1
phase with a concomitant decrease (p < 0.05) in the Sphase as compared to the control (Figure 3). A significant
increase (p < 0.05) in the number of cells at G2/M phase
was noted at 50 μg/mL of DCM-DS. The sub-G1 popu-









Figure 2 DCM-DS inhibited the growth of MCF-7 cells. (A) Morphological changes of MCF-7 cells after treatment with DCM-DS (100×) (B)
Effect of DCM-DS on MCF-7 cells at 48 hours (400×). Cellular shrinkage was observed in DCM-DS-treated MCF-7 cells (arrows). (C) Changes in
number of cell (percentage) treated with DCM-DS for 24, 48 and 72 hours. * is significantly different (p < 0.05).
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BG0/G1 = 68.79 ± 6.26
S      = 15.93 ± 5.59 
G2 /M = 15.29 ± 1.17*
G0 /G1 = 65.39 ± 6.22
S      = 20.12 ± 8.13 
G2 /M = 14.50 ± 1.93*
G0/G1 = 88.18 ± 0.16*
S      = 6.75 ± 0.34* 
G2/M =    5.08 ± 0.25
G0/G1= 87.35 ± 0.58*
S      = 6.14 ± 0.74*
G2/M =    6.52 ± 1.01
G0/G1= 80.21 ± 1.92*
S      = 13.04 ± 0.88* 
G2/M =    6.75 ± 0.34
G0/G1 = 75.68 ± 2.38*
S      = 13.42 ± 1.54* 
G2/M = 10.90 ± 0.10
G0/G1 = 75.07 ± 1.61*
S      = 15.53 ± 2.09* 
G2/M =  9.40 ± 0.58
G0/G1= 67.49 ± 3.03
S      = 23.31 ± 1.17 
































































































24 hours 48 hours 72 hours
Control
G0/G1 = 68.83 ± 1.01
S    = 22.85 ± 2.94
G2/M =    8.33 ± 1.97
G0/G1 = 65.51 ± 1.01
S      = 25.70 ± 0.56 
G2/M =    8.79±1.53
G0/G1 = 83.20 ± 0.80*
S      = 10.33 ± 0.62* 
G2/M =    6.48 ± 0.56
A
Figure 3 Cell cycle profile of MCF-7 cells treated with DCM-DS (A and B). The cell cycle profile of 50 μg/mL at 72 hours was not able to be
determined due to the extensive formation of cell debris. Each data point represents the mean of three independent experiments ± SD.
*significantly different from the control (p < 0.05).
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Treatment of MCF-7 cells with DCM-DS significantly
increased (p < 0.05) the percentage of early apoptotic cells
(Annexin-V+/PI−) as compared to the control (Figure 4A
and 4B). The percentage of early apoptotic cells for
12.5, 25 and 50 μg/mL at 48 hours were 29.1, 32.9 and
28.8%, respectively, as compared to the control (4.0%)
(Figure 4B). The percentage of dead cells or late apop-
totic cells (PI+) for 12.5, 25 and 50 μg/mL at 48 hours
were 12.8, 28.8 and 31.3%, respectively, as compared to
the control (11.9%).
DCM-DS induced formation of intracellular ROS in
MCF-7 cells
As shown in Figure 5A, the cells treated with DCM-DS
at 12.5 and 25 μg/mL significantly increased (p < 0.05)
the percentage of cells that expressed ROS to 55 and
26%, respectively, as compared to the 3% basal level.
ROS partially induced cell death in MCF-7 cells
As shown in Figure 5B, the viability of the cells treated
with DCM alone at 50 μg/mL for 24 and 48 hours were
24% and 3%, respectively. The co-treatment with 50 μM
antioxidant α-tocopherol and DCM-DS significantly
increased (p < 0.05) the viability of the cells to 48% and
50%, respectively. At 25 μg/mL of DCM-DS, co-treatment
with α-tocopherol significantly increased the viability of
the cells from 28% to 40% at 48 hours. In comparison,
cells co-treated with 50 μM ascorbic acid did not increase
or decrease in the viability of the cells at all the tested
concentrations.
DCM-DS regulated the apoptotic, growth and survival
genes in MCF-7 cells
Treatment of MCF-7 cells with DCM-DS significantly
up-regulated (p < 0.05) the expression of SOD1, SOD2,
CAT, p38MAPK, JNK and NF-κB in MCF-7 cells. On the
other hand, the expression of AKT1 and ERK1/2 were
significantly (p < 0.05) down-regulated in a dose-dependent
manner (Figure 6A).
DCM-DS up-regulated apoptotic protein and
down-regulated anti-apoptotic proteins in MCF-7 cells
Treatment of MCF-7 cells with DCM-DS significantly
up-regulated (p < 0.05) the expression of NF-κB, JNK1
and pJNK1. In addition, the expression of both AKT1 and
ERK1 were down-regulated by the treatment (Figure 6B).
Discussion
Breast cancer is the most frequent cancer among
women. Approximately 1.67 million new breast cancer
cases were reported in 2012, which accounts for 25% of
all new diagnosed cancer [25]. The current treatment
strategies for breast cancer patients such as surgery,chemotherapy and radiotherapy or the combination of
radiotherapy and chemotherapy have successfully in-
creased the five-year survival rate of the breast cancer
patients. Nevertheless, the long-term survival remains
poor due to cancer relapse and metastasis. D. suffruticosa
has a great potential as an anticancer agent due to its trad-
itional use for treatment of cancerous growth [18] and
based on our previous findings [22]. In the present study,
DCM-DS exhibited strong cytotoxic properties against
caspase-3 deficient MCF-7 cells (Figure 1A). According to
the National Cancer Institute guidelines, DCM-DS is a
great candidate to be developed as an anticancer agent for
breast cancer as the IC50 value was less than 20 μg/mL
towards MCF-7 cells after treatment for 72 hours [26].
In addition, DCM-DS was also toxic to the non-
tumourigenic MCF-10A cells (Figure 1B). Nevertheless,
MCF-10A cells were more resistant to the treatment of
DCM-DS as compared to the MCF-7 cells (the cell viabil-
ity of MCF-10A treated with 25 μg/mL at 72 hours was
45% as compared to the 15% cell viability in MCF-7 cells).
The morphological analysis has revealed that DCM-
DS-treated MCF-7 cells experienced cellular shrinkage,
suggesting induction of apoptosis in the cells (Figure 2A).
Inhibition of the cell growth at 12.5 and 25 μg/mL of
DCM-DS between 24 to 48 hours (Figure 2A) was due
to cell cycle arrest at G0/G1 phase as being confirmed by
the flow cytometry analysis. Nevertheless, DCM-DS at
50 μg/mL arrested the cells at G2/M instead of G0/G1
(Figure 3A and 3B) suggesting that the dose of an agent
may influence the effects on cell cycle.
The induction of apoptosis by DCM-DS in MCF-7
cells was ascertained by the Annexin-V-FITC/PI-flow
cytometry analysis (Figure 4A and 4B). Apoptosis is
characterized by distinct biochemical features in elimin-
ation of damaged cells or tumour cells without causing in-
flammation [27]. The activation of enzymatic and catabolic
processes in apoptosis thereby facilitate cell morphological
changes such as externalization of plasma membrane phos-
phatidylserine (PS), cellular shrinkage, membrane blebbing,
chromatin condensation, nuclear fragmentation and for-
mation of apoptotic bodies [28,29]. PS is a phospholipid
component which has a strong binding affinity towards
Annexin-V [30]. In a normal cell, PS is positioned on the
inner surface of the cell membrane and therefore inaccess-
ible to Annexin-V. At an early stage of apoptosis, PS is
translocated to the outside of the cell membrane and
bind with Annexin-V. PS translocation is an irrevers-
ible event. The apoptotic bodies formed are eventually
engulfed by phagocytes such as neutrophils and macro-
phages in in vivo. Since the in vitro system is lack of
phagocytes, the membrane of the apoptotic bodies will
rupture (also known as secondary necrosis) and accessible
to the PI dye. Therefore, secondary necrotic cells are
stained by both Annexin-V and PI [30].
Control
Annexin V















Figure 4 (See legend on next page.)
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Figure 4 The percentage of viable, apoptotic and necrotic/secondary necrotic cells of untreated and DCM-DS-treated MCF-7 cells for
24 and 48 hours as determined by flow cytometry. (A and B) These figures are from representative experiments carried out at least three
times. The percentage of viable cells was represented by the lower left quadrant (Annexin-V−/PI−); the percentage of early apoptotic and
necrotic/secondary necrotic cells were represented by the lower right (Annexin-V+/PI−) and upper (PI+) quadrants, respectively. Each data point
represents the mean of three independent experiments ± SD. *significantly different from the control (p < 0.05).
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tosis in MCF-7 cells, some other distinct morphological
features of apoptosis such as membrane blebbing, chro-
matin condensation, nuclear fragmentation and formation





Figure 5 Determination on the involvement of ROS in the cytotoxicit
DCM-DS-treated MCF-7 cells by using DCFH-DA (Sigma-Aldrich). (B) Cell via
24 and 48 hours. Each data point represents the mean of three independe
concentration at the same time point (p < 0.05).the sub-G1 population was also undetectable even at the
viability as low as < 10% in the treatment of 50 μg/mL
DCM-DS at 48 hours (Figure 3). These observations could
be due to the caspase-3 deficiency in the MCF-7 cells that
were used in the present study which has been confirmedy of DCM-DS in MCF-7 cells. (A) Measurement of intracellular ROS in
bility of MCF-7 cells co-treated with α-tocopherol or ascorbic acid for







1.0 1.121.04 1.15 1.0 1.34*1.70* 0.86
1.0 0.76*0.75* 0.99 1.0 0.72*0.68* 1.26
1.0 0.760.87 0.82 1.0 0.58*0.70* 0.58*
1.0 2.04*1.46* 2.96* 1.0 0.490.58 0.70
1.0 0.800.93 0.96 1.0 1.32*1.24 1.34*
µg/mL
24 hours 48 hours
Control 2512.5 50 Control 2512.5 50
A
Figure 6 Expression levels of genes and proteins in MCF-7 cells following treatment with DCM-DS. (A) Relative fold change of gene
expression in DCM-DS-treated MCF-7 cells at 24 hours as compared to the control. (B) Western blot analysis of the expression of NF-κB, JNK1,
pJNK1, AKT1, ERK1and beta-actin from DCM-DS-treated MCF-7 cells. Fold change was normalised against beta-actin and compared to the control.
Each data point represents the mean of three independent experiments ± SD. *significantly different from the control (p < 0.05).
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there was no detectable caspase-3 in MCF-7 cells at
mRNA level (unpublished data). Caspase-3 is crucial for
typical biochemical and morphological changes of cells
undergoing apoptosis such as nuclear fragmentation.
Several investigators have reported that MCF-7 cells
originated from ATCC was caspase-3 deficiency and
the typical characteristics of apoptosis were absent in
this cell line upon treatment with apoptosis inducing
agents [31-33]. Molecular study has uncovered the
caspase-3 deficiency in this cell line is caused by a 47-base
pair deletion within exon 3 of the CASP-3 resulting in the
skipping of this exon during pre-mRNA splicing and
introduction of a premature stop codon at position 42
that completely abrogates translation of the CASP-3
mRNA [33]. Nevertheless, sub-G1 population (<10%) wasdetectable following 72 hours exposure of DCM-DS at
12.5 and 25 μg/mL (Figure 3). It is then postulated that
the caspase-3-deficient MCF-7 cells underwent aberrant
nuclear and cytoplasmic destruction, leading to high
molecular weight DNA fragmentation upon treatment
with DCM-DS that could be mistaken for the typical
apoptotic (low molecular) DNA fragmentation [31,34].
Since DCM-DS induced cell cycle arrest and apoptosis
in the caspase-3-deficient-MCF-7 cells, it is suggested that
the induction of apoptosis is via caspase-3-independent
pathways.
Further investigation on molecular pathways involved in
the induction of apoptosis by DCM-DS was performed by
using GeXP-based multiplex system. Expression of SOD1,
SOD2 and CAT was up-regulated following treatment




JNK, NF-κB ↑ AKT1, ERK1/2 ↓
Apoptosis
Figure 7 Proposed schematic diagram of the mechanism by
which DCM-DS induced apoptosis in caspase-3 deficient MCF-7
cells. DCM-DS induced cell cycle arrest in MCF-7 cells. In addition,
DCM-DS up-regulated NF-κB, JNK1 and down-regulated AKT1, ERK1,
resulting in apoptosis in caspase-3 deficient MCF-7 cells.
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this has been confirmed by evaluating the ROS level
(Figure 5A). The up-regulation of several antioxidant
defence genes such as SOD and CAT is to protect the
cells from harmful ROS, keeping them in normoxidant
state [36]. The production of ROS such as hydrogen
peroxide (H2O2), superoxide radicals (O2
−) and hydroxyl
radicals (OH−) is a consequence of incomplete reduction
of oxygen molecules in the mitochondrial electron trans-
port chain during respiration which impaired the normal
cellular functions [37]. SOD1 and SOD2 code for copper-
zinc superoxide dismutase and manganese superoxide dis-
mutase, respectively, which scavenge the O2
− into H2O2
and molecular oxygen (O2). H2O2 is then converted to
water by either catalase (coded by CAT), glutathione per-
oxidase, or peroxiredoxins [38]. It has been well known
for decades that H2O2 exerts dose-dependent effects on
cellular activities, from growth stimulation at very low
concentration to growth arrest, apoptosis, and eventually
necrosis as the concentration increases. It seems that ROS
play dual roles, either beneficial or deleterious, depending
on the level in living cells [35,39]. To investigate whether
the cell death in the present study was mainly due to ROS,
the cells were co-treated with antioxidant α-tocopherol and
ascorbic acid (Figure 5B). The results showed that α-
tocopherol and ascorbic acid did not block the reduction of
cell viability at 12.5 and 25 μg/mL of DCM-DS, suggesting
that ROS did not involve in the event at these two concen-
trations. Nevertheless, at high concentration of DCM-DS
(50 μg/mL), the co-treatment with α-tocopherol sig-
nificantly blocked the cell death, suggesting that high
concentration of DCM-DS induced the formation of
ROS which played a significant role to induce cell death in
MCF-7 cells.
The expression of AKT1 gene and the protein (Figure 6)
were down-regulated in the present study suggesting the
involvement of Akt pathway in DCM-DS-induced apop-
tosis. Other studies have shown that apoptosis in MCF-7
cells was related to the inhibition of Akt signalling pathway
after treatment with Wogonin or retinoic-acid [40,41]. Akt
is a serine-threonine kinase that facilitates the control
of balance between survival and apoptosis. The activa-
tion of AKT1 has been reported to protect the cells
from oxidative stress and orchestrate tumourigenesis in
animal model [5-8]. JNK is a stress responsive kinase.
The activation of JNK has been reported to induce
apoptosis in various cancer cells including MCF-7 cells
[10]. In this study, JNK gene was up-regulated more
than 2 folds following treatment with DCM-DS which
was then confirmed by the Western blot analysis, sug-
gesting that the activation of JNK could be due to the
bioactive compounds present in the DCM-DS, which in
turn induced growth inhibition and apoptosis in MCF-7
cells [9-12].The NF-κB was initially characterized as a central
regulator in response to pathogens and viruses [42].
Although compelling experimental data have identified
NF-κB as a tumour-promoting transcription factor,
recent studies have unravelled the function of NF-κB
as one of the key players of apoptosis [16,17]. It means
that NF-κB could be pro-or-anti-apoptotic protein. It has
been reported that up-regulation of AKT and ERK1/2,
which in turn activates the NF-κB resulting in the metas-
tasis of breast cancer cells to the bone [43]. In contrast,
treatment with DCM-DS up-regulated the expression of
NF-κB in MCF-7 cells despite of the down-regulation of
AKT1 and ERK1/2. It has also been demonstrated that
NF-κB pathway may function independently from Akt
pathway [44]. Hence, it is postulated that although some
crosstalks exist between Akt and NF-κB pathway in re-
sponse to DCM-DS-induced oxidative stress in MCF-7
cells, but it appears that these two pathways can act in-
dependently. Nevertheless, the up-regulation of NF-κB
in the current study remains to be elucidated.
The molecular mechanisms underlying the cytotoxicity
of DCM-DS on MCF-7 cells are proposed in Figure 7.
The shift of attention towards bioactive compounds and
understanding of its mechanism of action are utmost
essential to discover the potential of the extract in
breast cancer intervention. Previous study reported
that triterpenes appear to be the major compounds in
DCM-DS that could be responsible to regulate the signal-
ling pathways in the present study [22]. Several triterpenes
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to induce apoptosis in cancer cells via regulation of
MAPKs [13,45-48]. Nevertheless, a study will be carried
out to isolate and characterise the bioactive compounds
present in the DCM-DS that are responsible in the
caspase-3 deficient MCF-7 cell death.
Breast cancer is a complex and heterogeneous disease
that has been molecularly classified into 4 major subtypes:
Luminal A, Luminal B, human epidermal growth receptor
2 (HER2) and basal-like breast cancers [49,50]. The
caspase-3 deficient MCF-7 cells used in the present study
fell to Luminal A subtype which accounts for approxi-
mately 40% of the total breast cancer cases [51]. Neverthe-
less, a future study should be conducted to evaluate the
therapeutic effect of DCM-DS towards other breast cancer
subtypes especially the basal-like breast cancer subtype
which has the worst prognosis, metastasis to lung and
brain, and high mortality rate (death within the first 3–5
years of diagnosis) as compared to other breast cancer
subtypes [52,53].Conclusion
DCM-DS induced cell cycle arrest and apoptosis in
caspase-3 deficient MCF-7 cells possibly via the up-
regulation of NF-κB, JNK1 and down-regulation of
AKT1 and ERK1. Therefore, DCM-DS has a great
potential to be developed to target the cancer cells
with mutant caspase-3.Competing interests
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